SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ • Healthcare

$11.55

-$1.93 (-14.4%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$13.55

Day Range$11.38 - $13.74

Avg. Volume (3M)7.7M

Market Cap$2.1B

52 Week Range

$1.39$15.88

Next EarningsIn 59 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$32.4M

EPS (TTM)

-$0.21

ROA (TTM)

-22.33%

Current Ratio

18.83

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+16.0%Q3 2025-$0.07

+5.3%Q4 2025-$0.06

+21.0%Q1 2026-$0.05

+16.7%Q2 2026-$0.05

-11.1%Q3 2026-$0.05

Nov 11

in 59 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -11.1%

Net income widened year over year for SELLAS Life Sciences Group in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026. The company posted a GAAP net loss of roughly $9.6 million, down 45.5% from a net loss of about $6.6 million a year ago, as it continued investing in its late-stage oncology immunotherapy programs such as galinpepimut-S (GPS) and nelipepimut-S. Operating income was about -$10.6 million, while EPS came in at -$0.05. Cash usage remained elevated, with negative operating cash flow of roughly $7.6 million for the quarter. For the next period, consensus calls for EPS of -$0.05.

View full earnings history

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a NASDAQ-listed healthcare company in the Biotechnology field that operates as a late-stage biopharmaceutical developer focused on novel cancer immunotherapies. In qualitative terms it is a small-cap biotech centered on oncology candidates, with its work concentrated in the United States.

Name

SELLAS Life Sciences Group, Inc.

CEO

Angelos Stergiou

Website

www.sellaslifesciences.com

Industry

Healthcare

Year Founded

2012

Employees

Today's Snapshot

AI-generated

The day ended with SLS 14.4% lower at 11.54, while its sector was flat. Volume was roughly twice its usual level. Sellas faced legal probes and investor fears over dilution from new shares.

Trading Volume

Above 10d avg 7.1M

14.4M

vs S&P 500 Today

Strong Underperformance

-15.35%

Updated: September 11, 2026 at 20:26 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

SLS presents a sell-oriented technical picture with price below near-term moving averages and under the pivot, accompanied by negative momentum readings. CCI and short-term momentum are notably weak while RSI and stochastics are subdued, and ADX signals a trending environment that currently favors the downside. Volatility is high on a percentage basis and ATR reflects meaningful price swings; OBV also shows distributionary pressure. Despite the stock trading above longer-term averages, the short- to medium-term structure and volume profile support a bearish stance. Technical takeaway: Sell — short-term momentum and volume favor lower price action.

All signals

EMA (5 indicators)$7.71 - $13.34
Sell
RSI (14)40.76
Neutral
Stochastic %K (14, 3, 3)25.08
Neutral
MACD Level (12, 26)0.23
Neutral

Peers & Related Assets

GNFTGenfit S.A.

CCCCC4 Therapeutics, Inc.

PRLDPrelude Therapeutics Incorporated

IVVDInvivyd, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.